Investment analysts at UBS AG cut their target price on shares of Celgene (NASDAQ: CELG) from $85.00 to $78.00 in a note issued to investors on Friday. The firm currently has a “buy” rating on the stock.
Shares of Celgene traded up 1.93% during mid-day trading on Friday, hitting $60.59. Celgene has a 52 week low of $51.70 and a 52 week high of $80.42. The company has a market cap of $26.690 billion and a P/E ratio of 18.51.
Celgene last announced its earnings results on Thursday, April 26th. The company reported $1.08 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.13 by $0.05. The company’s revenue for the quarter was up 13.2% on a year-over-year basis. Analysts expect that Celgene will post $1.24 EPS next quarter.
A number of other analysts have also recently weighed in on CELG. Analysts at Morgan Stanley cut their price target on shares of Celgene to $75.00 in a research note to investors on Friday. They now have an “overweight” rating on the stock. Separately, analysts at Cantor Fitzgerald cut their price target on shares of Celgene from $90.00 to $73.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Finally, analysts at Benchmark Co. cut their price target on shares of Celgene from $90.00 to $73.00 in a research note to investors on Friday. They now have a “buy” rating on the stock.
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
Stay on top of analysts' coverage with our daily email newsletter that provides a concise list of analysts' upgrades, analysts' downgrades and analysts' price target changes for each day. Click here to register.